- Company
- Will the polycythemia vera drug Besremi be reimb in KOR?
- by Eo, Yun-Ho Nov 4, 2024 05:48am
- Whether PharmaEssentia Korea’s new drug for polycythemia vera, ‘BESREMi,’ will be listed with reimbursement in Korea is gaining attention. The drug was approved for hydroxyurea-refractory or intolerant polycythemia vera in March last year but failed to overcome the CDDC barrier in July of the same year. At that time, the CDDC dete
- Company
- K-Bios globally present immuno-oncology drugs
- by Son, Hyung Min Nov 4, 2024 05:48am
- The development achievements of the domestic pharmaceutical bio industry's immuno-oncology drugs will be presented at an overseas conference. Hanmi Pharmaceutical, GC Cell, Abion Bio, ST Cube, and Y-Biologics, among others, have completed preparations to emerge into the international stage by disclosing positive clinical trial results.&16
- Company
- Reimb of Vocabria+Rekambys for HIV gains attention
- by Eo, Yun-Ho Nov 4, 2024 05:48am
- The industry’s eyes are on whether the long-acting HIV combination therapy ‘Vocabria+Rekambys’ will be reimbursed by the end of the year in Korea. According to industry sources, GSK Korea and Janssen Korea have completed the pharmacoeconomic evaluation of their HIV drugs Vocabria (cabotegravir) and Rekambys (rilpivirine) combination
- Company
- New AML drug Vyxeos can be prescribed at Big 5 hospitals
- by Eo, Yun-Ho Nov 1, 2024 05:51am
- The new acute myeloid leukemia drug ‘Vyxeos’ may now be prescribed at general hospitals in Korea. According to industry sources, Vyxeos (daunorubicin+ cytarabine), a treatment for adults with acute myeloid leukemia AML, has passed the drug committees (DCs) of the ‘Big 5’ tertiary hospitals in Korea including the Samsung Medical Center
- Company
- Novartis’s operating income grew 123% in Q3 with Entresto
- by Son, Hyung Min Nov 1, 2024 05:50am
- The Swiss global pharmaceutical giant Novartis' sales increased slightly compared to the previous year. Novartis showed even sales growth in various therapeutic areas, including cardiovascular, anticancer, and immunosuppressive agents. According to industry sources, Novartis reported a revenue of USD 12.823 billion in Q3 last year, up 10% YoY
- Company
- Atopic dermatitis drug Ebglyss to enter Korea next year
- by Whang, byung-woo Oct 31, 2024 05:55am
- The atopic dermatitis drug Ebglyss (lebrikizumab), which is set to soon be released in Korea, has added competitivity by securing rationale for switching between biologics. The company plans to receive reimbursement after launching the drug without reimbursement early next year. At the recent Fall Clinical Dermatology conference that
- Company
- Oral ALS drug 'Radicava' likely to land in KOR
- by Eo, Yun-Ho Oct 31, 2024 05:55am
- 'Radicava,' an oral drug for the treatment of amyotrophic lateral sclerosis (ALS), is expected to be commercialized in South Korea. Sources said that Mitsubishi Tanabe Pharma Korea's Radicava (edaravone) is under consideration for domestic approval. The drug is a treatment for ALS, formerly known as Lou Gehrig's disease. Radicava is
- Company
- Pfizer's Q3 sales 31%↑amid increased demand for COVID-19
- by Son, Hyung Min Oct 31, 2024 05:55am
- The global pharmaceutical company Pfizer's sales are increasing compared to the previous year. Pfizer's growth has been driven by the sales of COVID-19 vaccines and treatments such as Paxlovid and Comirnaty. According to industry sources on October 30, Pfizer's sales in Q3 recorded US$17.72 billion (about KRW 24.48 trillion), up 31.2% year-ov
- Company
- NIP inclusion of HPV vaccines on the horizon
- by Whang, byung-woo Oct 31, 2024 05:55am
- Amid high interest in the expansion of the National Immunization Program (NIP) to include HPV vaccines, the possibility of its inclusion in 2026 has arisen in Korea. Although the agenda is yet in the planning stage, attention is being paid to whether it can gain substance in line with the NA budget deliberation discussions next month.
- Company
- Difficulty expanding indications for antibody-drug conjugate
- by Moon, sung-ho Oct 30, 2024 05:54am
- Drug candidates that received much expectation as next-generation antibody-drug conjugates (ADCs) based on the success of Enhertu are on a struggling path to reimbursement in Korea. &160; Although the companies aimed to expand the scope of coverage of their drugs based on their effectiveness in specific cancer types, the expectations damped
